Intellia Therapeutics Announces Publication in Cell Reports of Preclinical Data Demonstrating Effective CRISPR/Cas9 Genome Editing Using Lipid Nanoparticle (LNP) Delivery Technology
Intellia researchers achieved 97 percent reduction in serum transthyretin protein levels in mice through a single administration, with a durability of at least 12 months CRISPR/Cas9 administered via LNP was well-tolerated with no observed adverse events CRISPR/Cas9 components shown to be
Intellia Therapeutics to Present at February Healthcare Investor Conferences
CAMBRIDGE, Mass. , Jan. 31, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, will present or host one-on-one meetings at the following upcoming healthcare
